You are here: Industry Insights > GSK

News List

GlaxoSmithKline opens new $56.6M vaccines plant in Scotland fiercepharma
August 16, 2017
GlaxoSmithKline has completed an addition to its Montrose site in Scotland that will expand its vaccine production capabilities.
GSK walks away from Ionis antisense drugs pharmatimes
August 15, 2017
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals' experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
GSK to close it neuroscience R&D center in China biospectrumasia
August 14, 2017
The lab led the firm’s research efforts in neurological diseases including Parkinson’s, multiple sclerosis, and Alzheimer’s
GSK announces new priorities; plans to offload 130 non-core brands biospectrumasia
August 03, 2017
In a major cost-saving drive, GSK plans to focus on ‘real winners’- medicines that generate substantial returns
GSK files supplementary NDA for asthma treatment arnuity ellipta pharmaceutical-technology
July 27, 2017
GSK has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the use of arnuity ellipta (fluticasone furoate) as a maintenance treatment of children with asthma.
GSK Pharma strengthens vaccine portfolio expressbpd
July 27, 2017
GST implementation impacts GSK’s June quarter performance
GSK chief reassured over ‘pragmatic’ Brexit approach pharmafile
July 27, 2017
Amongst other announcements at its second quarter statement, GSK’s CEO, Emma Walmsley, gave a hint towards the British-based company’s desires for the Brexit transition.
GSK Receives FDA Approval for New Self-Injectable Formulation of Benlysta americanpharmaceuticalreview
July 25, 2017
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody-positive SLE...
GSK files for extended use of Relvar Ellipta in asthma pharmatimes
July 25, 2017
GlaxoSmithKline and Innoviva have applied in Europe to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid long-acting β2-agonist therapy.
FDA approves GSK’s new self-injectable formulation for systemic lupus erythematosus biospectrumasia
July 25, 2017
Systemic Lupus Erythematosus (SLE) is the most common form of lupus, a chronic, incurable autoimmune disease producing auto-antibodies that can attack almost any system in the body.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page